An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

Michael R. Savona, Luca Malcovati, Rami Komrokji, Ramon V. Tiu, Tariq I. Mughal, Attilio Orazi, Jean Jacques Kiladjian, Eric Padron, Eric Solary, Raoul Tibes, Raphael Itzykson, Mario Cazzola, Ruben Mesa, Jaroslaw Maciejewski, Pierre Fenaux, Guillermo Garcia-Manero, Aaron Gerds, Guillermo Sanz, Charlotte M. Niemeyer, Francisco CervantesUlrich Germing, Nicholas C P Cross, Alan F. List

Research output: Contribution to journalArticle

Abstract

Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are hematologically diverse stem cell malignancies sharing phenotypic features of both myelodysplastic syndromes and myeloproliferative neoplasms. There are currently no standard treatment recommendations for most adult patients with MDS/MPN. To optimize efforts to improve the management and disease outcomes, it is essential to identify meaningful clinical and biologic end points and standardized response criteria for clinical trials. The dual dysplastic and proliferative features in these stem cell malignancies define their uniqueness and challenges. We propose response assessment guidelines to harmonize future clinical trials with the principal objective of establishing suitable treatment algorithms. An international panel comprising laboratory and clinical experts in MDS/MPN was established involving 3 independent academic MDS/MPN workshops (March 2013, December 2013, and June 2014). These recommendations are the result of this collaborative project sponsored by the MDS Foundation.

Original languageEnglish
Pages (from-to)1857-1865
Number of pages9
JournalBlood
Volume125
Issue number12
DOIs
Publication statusPublished - Mar 19 2015

Fingerprint

Stem cells
Myelodysplastic Syndromes
Neoplasms
Stem Cells
Clinical Trials
Disease Management
Guidelines
Education
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)

Cite this

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. / Savona, Michael R.; Malcovati, Luca; Komrokji, Rami; Tiu, Ramon V.; Mughal, Tariq I.; Orazi, Attilio; Kiladjian, Jean Jacques; Padron, Eric; Solary, Eric; Tibes, Raoul; Itzykson, Raphael; Cazzola, Mario; Mesa, Ruben; Maciejewski, Jaroslaw; Fenaux, Pierre; Garcia-Manero, Guillermo; Gerds, Aaron; Sanz, Guillermo; Niemeyer, Charlotte M.; Cervantes, Francisco; Germing, Ulrich; Cross, Nicholas C P; List, Alan F.

In: Blood, Vol. 125, No. 12, 19.03.2015, p. 1857-1865.

Research output: Contribution to journalArticle

Savona, MR, Malcovati, L, Komrokji, R, Tiu, RV, Mughal, TI, Orazi, A, Kiladjian, JJ, Padron, E, Solary, E, Tibes, R, Itzykson, R, Cazzola, M, Mesa, R, Maciejewski, J, Fenaux, P, Garcia-Manero, G, Gerds, A, Sanz, G, Niemeyer, CM, Cervantes, F, Germing, U, Cross, NCP & List, AF 2015, 'An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults', Blood, vol. 125, no. 12, pp. 1857-1865. https://doi.org/10.1182/blood-2014-10-607341
Savona, Michael R. ; Malcovati, Luca ; Komrokji, Rami ; Tiu, Ramon V. ; Mughal, Tariq I. ; Orazi, Attilio ; Kiladjian, Jean Jacques ; Padron, Eric ; Solary, Eric ; Tibes, Raoul ; Itzykson, Raphael ; Cazzola, Mario ; Mesa, Ruben ; Maciejewski, Jaroslaw ; Fenaux, Pierre ; Garcia-Manero, Guillermo ; Gerds, Aaron ; Sanz, Guillermo ; Niemeyer, Charlotte M. ; Cervantes, Francisco ; Germing, Ulrich ; Cross, Nicholas C P ; List, Alan F. / An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. In: Blood. 2015 ; Vol. 125, No. 12. pp. 1857-1865.
@article{7b38c0198d3843199a154f11e7676e15,
title = "An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults",
abstract = "Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are hematologically diverse stem cell malignancies sharing phenotypic features of both myelodysplastic syndromes and myeloproliferative neoplasms. There are currently no standard treatment recommendations for most adult patients with MDS/MPN. To optimize efforts to improve the management and disease outcomes, it is essential to identify meaningful clinical and biologic end points and standardized response criteria for clinical trials. The dual dysplastic and proliferative features in these stem cell malignancies define their uniqueness and challenges. We propose response assessment guidelines to harmonize future clinical trials with the principal objective of establishing suitable treatment algorithms. An international panel comprising laboratory and clinical experts in MDS/MPN was established involving 3 independent academic MDS/MPN workshops (March 2013, December 2013, and June 2014). These recommendations are the result of this collaborative project sponsored by the MDS Foundation.",
author = "Savona, {Michael R.} and Luca Malcovati and Rami Komrokji and Tiu, {Ramon V.} and Mughal, {Tariq I.} and Attilio Orazi and Kiladjian, {Jean Jacques} and Eric Padron and Eric Solary and Raoul Tibes and Raphael Itzykson and Mario Cazzola and Ruben Mesa and Jaroslaw Maciejewski and Pierre Fenaux and Guillermo Garcia-Manero and Aaron Gerds and Guillermo Sanz and Niemeyer, {Charlotte M.} and Francisco Cervantes and Ulrich Germing and Cross, {Nicholas C P} and List, {Alan F.}",
year = "2015",
month = "3",
day = "19",
doi = "10.1182/blood-2014-10-607341",
language = "English",
volume = "125",
pages = "1857--1865",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

AU - Savona, Michael R.

AU - Malcovati, Luca

AU - Komrokji, Rami

AU - Tiu, Ramon V.

AU - Mughal, Tariq I.

AU - Orazi, Attilio

AU - Kiladjian, Jean Jacques

AU - Padron, Eric

AU - Solary, Eric

AU - Tibes, Raoul

AU - Itzykson, Raphael

AU - Cazzola, Mario

AU - Mesa, Ruben

AU - Maciejewski, Jaroslaw

AU - Fenaux, Pierre

AU - Garcia-Manero, Guillermo

AU - Gerds, Aaron

AU - Sanz, Guillermo

AU - Niemeyer, Charlotte M.

AU - Cervantes, Francisco

AU - Germing, Ulrich

AU - Cross, Nicholas C P

AU - List, Alan F.

PY - 2015/3/19

Y1 - 2015/3/19

N2 - Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are hematologically diverse stem cell malignancies sharing phenotypic features of both myelodysplastic syndromes and myeloproliferative neoplasms. There are currently no standard treatment recommendations for most adult patients with MDS/MPN. To optimize efforts to improve the management and disease outcomes, it is essential to identify meaningful clinical and biologic end points and standardized response criteria for clinical trials. The dual dysplastic and proliferative features in these stem cell malignancies define their uniqueness and challenges. We propose response assessment guidelines to harmonize future clinical trials with the principal objective of establishing suitable treatment algorithms. An international panel comprising laboratory and clinical experts in MDS/MPN was established involving 3 independent academic MDS/MPN workshops (March 2013, December 2013, and June 2014). These recommendations are the result of this collaborative project sponsored by the MDS Foundation.

AB - Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are hematologically diverse stem cell malignancies sharing phenotypic features of both myelodysplastic syndromes and myeloproliferative neoplasms. There are currently no standard treatment recommendations for most adult patients with MDS/MPN. To optimize efforts to improve the management and disease outcomes, it is essential to identify meaningful clinical and biologic end points and standardized response criteria for clinical trials. The dual dysplastic and proliferative features in these stem cell malignancies define their uniqueness and challenges. We propose response assessment guidelines to harmonize future clinical trials with the principal objective of establishing suitable treatment algorithms. An international panel comprising laboratory and clinical experts in MDS/MPN was established involving 3 independent academic MDS/MPN workshops (March 2013, December 2013, and June 2014). These recommendations are the result of this collaborative project sponsored by the MDS Foundation.

UR - http://www.scopus.com/inward/record.url?scp=84925379434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925379434&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-10-607341

DO - 10.1182/blood-2014-10-607341

M3 - Article

C2 - 25624319

AN - SCOPUS:84925379434

VL - 125

SP - 1857

EP - 1865

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -